Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
-
Publication Venue For
-
TUMOR MUTATIONAL BURDEN AS A PREDICTOR OF IMMUNOTHERAPY RESPONSE: IS MORE ALWAYS BETTER?
2020
-
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma..
26:6039-6050.
2020
-
The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts..
26:5809-5813.
2020
-
Ipilimumab and Radiation in Patients with High Risk Resected or Regionally Advanced Melanoma.
2020
-
TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions..
26:5914-5925.
2020
-
Checking the Hippo in sarcomatoid renal cell carcinoma with immunotherapy.
2020
-
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)..
26:5411-5423.
2020
-
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma..
26:5297-5303.
2020
-
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?.
26:5287-5296.
2020
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
2020
-
Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting..
26:4743-4747.
2020
-
Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in Pten-deleted Mouse Models of Sarcoma..
26:5036-5047.
2020
-
Targeting isocitrate dehydrogenase mutations in cancer: emerging evidence and diverging strategies.
2020
-
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer..
26:4616-4624.
2020
-
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
2020
-
Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer..
26:4670-4681.
2020
-
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma..
26:4225-4232.
2020
-
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study..
26:4268-4279.
2020
-
Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer..
26:4010-4017.
2020
-
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis..
26:3928-3935.
2020
-
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy..
26:3589-3596.
2020
-
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition..
26:3803-3818.
2020
-
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer..
26:3557-3564.
2020
-
Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic..
26:3100-3103.
2020
-
Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators..
26:3079-3090.
2020
-
Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy..
26:3831-3842.
2020
-
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer..
26:3608-3615.
2020
-
A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2)..
26:3035-3043.
2020
-
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis..
26:2838-2848.
2020
-
Telomere Attrition in Childhood Cancer Survivors..
26:2281-2283.
2020
-
A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer..
26:1997-2010.
2020
-
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial..
26:1586-1594.
2020
-
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers..
26:1349-1358.
2020
-
Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions..
26:1277-1287.
2020
-
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218..
26:1288-1296.
2020
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer..
26:1009-1016.
2020
-
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease..
26:1141-1151.
2020
-
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
2020
-
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)..
25:7497-7505.
2019
-
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors..
25:6852-6867.
2019
-
The Evolving Modern Management of Brain Metastasis..
25:6570-6580.
2019
-
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)..
25:6073-6079.
2019
-
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN..
25:6080-6088.
2019
-
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)..
25:5493-5502.
2019
-
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy..
25:5584-5594.
2019
-
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer..
25:5388-5397.
2019
-
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy..
25:4202-4210.
2019
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice..
25:4264-4270.
2019
-
Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46..
25:4128-4140.
2019
-
Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome..
25:4155-4167.
2019
-
The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy..
25:3732-3743.
2019
-
Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities..
25:2963-2968.
2019
-
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells..
25:2783-2794.
2019
-
Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study..
25:2725-2736.
2019
-
Challenges with Novel Clinical Trial Designs: Master Protocols..
25:2049-2057.
2019
-
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies..
25:2042-2048.
2019
-
Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study..
25:1494-1504.
2019
-
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis..
25:1165-1173.
2019
-
Precision Medicine Approaches When Prostate Cancer Akts Up..
25:901-903.
2019
-
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response..
25:1036-1049.
2019
-
The Role of Angiogenesis in Hepatocellular Carcinoma..
25:912-920.
2019
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers..
25:43-51.
2019
-
Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts..
25:358-368.
2019
-
Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy..
25:9-11.
2019
-
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling..
24:6355-6366.
2018
-
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma..
24:6150-6159.
2018
-
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial..
24:5860-5872.
2018
-
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations..
24:5347-5356.
2018
-
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer..
24:5292-5304.
2018
-
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer..
24:5225-5232.
2018
-
Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients..
24:5012-5017.
2018
-
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
24:4874-4886.
2018
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)..
24:4734-4744.
2018
-
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
24:4771-4784.
2018
-
Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer..
24:4271-4281.
2018
-
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma..
24:4175-4186.
2018
-
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure..
24:3519-3527.
2018
-
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma..
24:3611-3631.
2018
-
T-cell Dysfunction in Glioblastoma: Applying a New Framework..
24:3792-3802.
2018
-
Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture..
24:2539-2547.
2018
-
The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis..
24:2616-2630.
2018
-
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses..
24:2285-2293.
2018
-
TGFβ1 Genetic Variants Predict Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy..
24:2225-2233.
2018
-
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study..
24:1554-1561.
2018
-
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.
24:1344-1354.
2018
-
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)..
24:1486-1499.
2018
-
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE..
24:737-743.
2018
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer..
24:316-325.
2018
-
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab..
23:7474-7482.
2017
-
In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior..
23:7531-7542.
2017
-
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression..
23:7034-7046.
2017
-
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment..
23:6616-6628.
2017
-
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer..
23:5687-5695.
2017
-
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype..
23:6094-6100.
2017
-
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study..
23:5066-5073.
2017
-
Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts..
23:4865-4874.
2017
-
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials..
23:3628-3637.
2017
-
Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer..
23:3428-3441.
2017
-
Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer..
23:3139-3149.
2017
-
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer..
23:1886-1890.
2017
-
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination..
23:1898-1909.
2017
-
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer..
23:1346-1357.
2017
-
Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer..
23:985-991.
2017
-
Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk..
23:6-8.
2017
-
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis..
22:5706-5712.
2016
-
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma..
22:5461-5471.
2016
-
Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity..
22:5164-5166.
2016
-
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI..
22:5079-5086.
2016
-
Cyst Fluid Analysis in Pancreatic Intraductal Papillary Mucinous Neoplasms..
22:4966-4967.
2016
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy..
22:4890-4900.
2016
-
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors..
22:4574-4584.
2016
-
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential..
22:4236-4248.
2016
-
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma..
22:3593-3605.
2016
-
Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials..
22:3138-3147.
2016
-
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors..
22:3560-3570.
2016
-
A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases..
22:2575-2582.
2016
-
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
22:2301-2310.
2016
-
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer..
22:1713-1724.
2016
-
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
22:935-947.
2016
-
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma..
22:582-595.
2016
-
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas..
22:1011-1017.
2016
-
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation..
22:319-327.
2016
-
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma..
22:470-478.
2016
-
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium..
21:5264-5276.
2015
-
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer..
21:5121-5130.
2015
-
Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities..
21:4970-4984.
2015
-
Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma..
21:4868-4880.
2015
-
Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch..
21:4505-4507.
2015
-
CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations..
21:4248-4250.
2015
-
Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing..
21:3442-3452.
2015
-
XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A..
21:3286-3297.
2015
-
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer..
21:2127-2137.
2015
-
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth..
21:1652-1664.
2015
-
Circulating tumor cell analysis in metastatic triple-negative breast cancers..
21:1098-1105.
2015
-
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)..
21:1078-1086.
2015
-
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer..
21:955-961.
2015
-
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes..
21:870-881.
2015
-
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program..
21:819-832.
2015
-
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma..
21:585-593.
2015
-
Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study..
21:756-762.
2015
-
Differential platelet levels affect response to taxane-based therapy in ovarian cancer..
21:602-610.
2015
-
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer..
21:448-459.
2015
-
Modernizing the diagnostic and decision-making pathway for prostate cancer..
20:6254-6257.
2014
-
Immunotherapy for primary brain tumors: no longer a matter of privilege..
20:5620-5629.
2014
-
Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study..
20:5331-5338.
2014
-
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma..
20:5113-5123.
2014
-
Erratum: Prevalence and clinical implications of epstein-barr virus infection inDeNovo diffuse large B-Cell lymphoma in Western Countries (Clin Cancer Res (2014) 20 (2338-2349)).
20:4974.
2014
-
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen..
20:4218-4227.
2014
-
Toward a drug development path that targets metastatic progression in osteosarcoma..
20:4200-4209.
2014
-
Aggressive Variants of Castration-Resistant Prostate Cancer.
20:2846-2850.
2014
-
Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer..
20:2740-2750.
2014
-
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells..
20:2684-2694.
2014
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries..
20:2338-2349.
2014
-
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia..
20:2092-2103.
2014
-
Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer..
20:1566-1575.
2014
-
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss..
20:972-984.
2014
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial..
20:490-498.
2014
-
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer..
20:480-489.
2014
-
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma..
20:68-75.
2014
-
Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients..
20:265-272.
2014
-
αB-crystallin: a novel regulator of breast cancer metastasis to the brain..
20:56-67.
2014
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer..
19:6891-6901.
2013
-
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)..
19:6957-6966.
2013
-
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803..
19:5777-5787.
2013
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer..
19:5505-5512.
2013
-
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class..
19:4951-4960.
2013
-
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy..
19:4717-4727.
2013
-
BRAF in melanoma: current strategies and future directions..
19:4326-4334.
2013
-
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology..
19:4315-4325.
2013
-
Is conflict of interest becoming a challenge for institution-based institutional review boards?.
19:4034-4039.
2013
-
Erratum: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E
colorectal cancer (Clinical Cancer Research (2013) 19 (2688-98)).
19:4018.
2013
-
Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation..
19:2929-2940.
2013
-
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer..
19:2688-2698.
2013
-
The imaging viewpoint: how imaging affects determination of progression-free survival..
19:2621-2628.
2013
-
Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease..
19:2420-2431.
2013
-
PAK1 mediates resistance to PI3K inhibition in lymphomas..
19:1106-1115.
2013
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma..
19:900-908.
2013
-
Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells..
19:549-559.
2013
-
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy..
19:491-499.
2013
-
Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer..
19:148-157.
2013
-
Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer..
18:6089-6095.
2012
-
Regulatory T cells move in when gliomas say "I Do"..
18:6086-6088.
2012
-
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer..
18:5489-5498.
2012
-
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101..
18:5099-5109.
2012
-
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer..
18:4820-4829.
2012
-
Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6..
18:4612-4620.
2012
-
TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep)..
18:4201-4212.
2012
-
FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma..
18:3780-3790.
2012
-
Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma..
18:3328-3339.
2012
-
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure..
18:3170-3179.
2012
-
Metformin use is associated with better survival of diabetic patients with pancreatic cancer..
18:2905-2912.
2012
-
Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer..
18:1404-1414.
2012
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303..
18:577-584.
2012
-
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups..
18:256-262.
2012
-
IL-6 and ovarian cancer--letter..
17:7837.
2011
-
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate..
17:7634-7644.
2011
-
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis..
17:7324-7336.
2011
-
Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma..
17:7015-7023.
2011
-
Achieving the goals of effective, safe, and individualized cancer care..
17:6632-6633.
2011
-
High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma..
17:6542-6552.
2011
-
Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".
17.
2011
-
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival..
17:6356-6366.
2011
-
Better late than early: FDG-PET imaging in metastatic renal cell carcinoma..
17:5841-5843.
2011
-
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing..
17:6061-6070.
2011
-
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype..
17:5822-5832.
2011
-
Introducing CCR perspectives in drug approval..
17:4929.
2011
-
Cytotoxic T-lymphocyte-associated antigen-4..
17:4622-4628.
2011
-
Is cytomegalovirus a therapeutic target in glioblastoma?.
17:4619-4621.
2011
-
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients..
17:4844-4853.
2011
-
Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer..
17:4531-4540.
2011
-
Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary..
17:4063-4070.
2011
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma..
17:4119-4124.
2011
-
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing..
17:3742-3750.
2011
-
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer..
17:3408-3419.
2011
-
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia..
17:2679-2692.
2011
-
Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics..
17:2549-2560.
2011
-
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma..
17:1915-1923.
2011
-
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis..
17:1632-1640.
2011
-
Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas..
17:1502-1508.
2011
-
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib..
17:1190-1199.
2011
-
Serum biomarker panels for the detection of pancreatic cancer..
17:805-816.
2011
-
Clinical correlates of NRAS and BRAF mutations in primary human melanoma..
17:229-235.
2011
-
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study..
16:6100-6110.
2010
-
Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer..
16:5390-5401.
2010
-
No evidence of sex-related survival disparities among head and neck cancer patients receiving similar multidisciplinary care: a matched-pair analysis..
16:5019-5027.
2010
-
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors..
16:4876-4883.
2010
-
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts..
16:4313-4318.
2010
-
NF1 inactivation in adult acute myelogenous leukemia..
16:4135-4147.
2010
-
CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis.
16:3875-3886.
2010
-
High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma..
16:3734-3742.
2010
-
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men..
16:3539-3547.
2010
-
A functional variant of tandem repeats in human telomerase gene was associated with survival of patients with early stages of non-small cell lung cancer..
16:3779-3785.
2010
-
Complement factor H autoantibodies are associated with early stage NSCLC..
16:3226-3231.
2010
-
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer..
16:3057-3066.
2010
-
Epigenetic markers in rectal cancer..
16:2699-2701.
2010
-
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules..
16:2167-2175.
2010
-
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer..
16:1938-1949.
2010
-
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity..
16:1466-1477.
2010
-
Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer..
16:1416-1422.
2010
-
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes..
16:1642-1651.
2010
-
Introducing new strategies in....
16:1347.
2010
-
Inherited determinants of ovarian cancer survival..
16:995-1007.
2010
-
Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics..
16:764-774.
2010
-
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer..
16:203-211.
2010
-
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity..
16:320-329.
2010
-
Barriers to integrating gene profiling for stage II colon cancer.
15:7451-7452.
2009
-
Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma..
15:7553-7561.
2009
-
Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients..
15:7737-7743.
2009
-
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803..
15:7322-7329.
2009
-
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia..
15:6947-6955.
2009
-
A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action..
15:6921-6930.
2009
-
Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity..
15:6367-6377.
2009
-
An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset..
15:6292-6300.
2009
-
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy..
15:4993-5001.
2009
-
Phase I trial of pazopanib in patients with advanced cancer..
15:4220-4227.
2009
-
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth..
15:4095-4103.
2009
-
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression..
15:3163-3171.
2009
-
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine..
15:2789-2796.
2009
-
Role of eotaxin-1 signaling in ovarian cancer..
15:2647-2656.
2009
-
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome..
15:2448-2455.
2009
-
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803..
15:2116-2122.
2009
-
Targeting Akt3 signaling in malignant melanoma using isoselenocyanates..
15:1674-1685.
2009
-
Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer..
15:1376-1383.
2009
-
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme..
15:1064-1068.
2009
-
DNA repair gene polymorphisms and risk of pancreatic cancer..
15:740-746.
2009
-
Genomic and molecular profiling predicts response to temozolomide in melanoma..
15:502-510.
2009
-
Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women..
15:400-405.
2009
-
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors..
15:374-381.
2009
-
RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects..
15:190-200.
2009
-
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas..
14:7068-7073.
2008
-
Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma..
14:7043-7049.
2008
-
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin..
14:6478-6486.
2008
-
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer..
14:6270-6276.
2008
-
CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck..
14:6343-6349.
2008
-
Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators..
14:6042-6054.
2008
-
Statistical challenges in preprocessing in microarray experiments in cancer..
14:5959-5966.
2008
-
Statistical issues in translational cancer research..
14:5954-5958.
2008
-
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells..
14:5759-5768.
2008
-
The Translational Research Working Group developmental pathway for image-based assessment modalities..
14:5678-5684.
2008
-
Translational Research Working Group developmental pathway for immune response modifiers..
14:5692-5699.
2008
-
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma..
14:5548-5554.
2008
-
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease..
14:5255-5259.
2008
-
Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives..
14:4685-4690.
2008
-
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma..
14:4859-4868.
2008
-
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma..
14:4500-4510.
2008
-
Molecular characterization of the pediatric preclinical testing panel..
14:4572-4583.
2008
-
Phase II trial of curcumin in patients with advanced pancreatic cancer..
14:4491-4499.
2008
-
Functional variants of the NEIL1 and NEIL2 genes and risk and progression of squamous cell carcinoma of the oral cavity and oropharynx..
14:4345-4352.
2008
-
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity..
14:3896-3905.
2008
-
A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population..
14:3633-3640.
2008
-
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma..
14:3156-3167.
2008
-
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies..
14:2756-2762.
2008
-
Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage "checkpoints" and lung cancer susceptibility..
14:2887-2891.
2008
-
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer..
14:2042-2048.
2008
-
Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells..
14:1997-2005.
2008
-
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study..
14:1124-1130.
2008
-
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples..
14:488-493.
2008
-
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies..
14:502-508.
2008
-
Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer..
13:7335-7340.
2007
-
The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma..
13:7228-7231.
2007
-
Defining cancer cachexia in head and neck squamous cell carcinoma..
13:6561-6567.
2007
-
Discussion: Issues in adjuvant therapy for early-stage disease.
13.
2007
-
Discussion: Surgical issues in colon and rectal cancers.
13.
2007
-
Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF..
13:6834-6841.
2007
-
New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference..
13:6853s-6856s.
2007
-
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report..
13:6712-6718.
2007
-
Radiation therapy in stage II and III rectal cancer..
13:6903s-6908s.
2007
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis..
13:6396-6403.
2007
-
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression..
13:6532-6539.
2007
-
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease..
13:6107-6114.
2007
-
Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer..
13:5736-5744.
2007
-
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma..
13:5418-5425.
2007
-
Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer..
13:4331-4335.
2007
-
Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck..
13:4300-4305.
2007
-
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin..
13:3968-3976.
2007
-
Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer..
13:3848-3854.
2007
-
Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma..
13:3125-3132.
2007
-
Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians..
13:3100-3104.
2007
-
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor..
13:2643-2650.
2007
-
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats..
13:3087-3099.
2007
-
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab..
13:2392-2399.
2007
-
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study..
13:2030-2037.
2007
-
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment..
13:2038-2045.
2007
-
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function..
13:2158-2167.
2007
-
The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3..
13:2271-2280.
2007
-
Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression..
13:1713-1719.
2007
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma..
13:1253-1259.
2007
-
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference..
13:667s-670s.
2007
-
Multiple etiologies of tumor hypoxia require multifaceted solutions..
13:375-377.
2007
-
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma..
13:753s-757s.
2007
-
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors..
13:576-583.
2007
-
Clinical and in vitro studies of imatinib in advanced carcinoid tumors..
13:234-240.
2007
-
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers..
12:7306-7315.
2006
-
A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation..
12:6800-6807.
2006
-
Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells..
12:6557-6564.
2006
-
Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy..
12:5733-5740.
2006
-
Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck..
12:5596-5602.
2006
-
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting..
12:5064-5073.
2006
-
An in vivo platform for translational drug development in pancreatic cancer..
12:4652-4661.
2006
-
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma..
12:4619-4627.
2006
-
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells..
12:4294-4305.
2006
-
Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors..
12:4004-4010.
2006
-
Activities and accomplishments of the cancer and leukemia group B genitourinary committee..
12:3596s-3600s.
2006
-
Cancer and leukemia group B gastrointestinal cancer committee..
12:3589s-3595s.
2006
-
The cancer and leukemia group B cancer in the elderly committee: addressing a major cancer need..
12:3606s-3611s.
2006
-
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia..
12:2662-2669.
2006
-
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme..
12:1970-1982.
2006
-
Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning..
12:1958-1960.
2006
-
A clinically proven, prospective, thermal dose descriptor exists [4].
12:1944-1946.
2006
-
Introducing CCR practice of translational oncology.
12:1657.
2006
-
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features..
12:1647-1653.
2006
-
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004)..
12:1540-1546.
2006
-
Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus..
12:1349-1354.
2006
-
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy..
12:819-826.
2006
-
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma..
12:860-868.
2006
-
Erythropoietin biology in cancer..
12:332-339.
2006
-
Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer..
12:152-158.
2006
-
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity..
12:289-297.
2006
-
Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray..
12:83-88.
2006
-
Immunonanoshells for selective photothermal therapy..
11:9097S-9097S.
2005
-
Nanoshells for combined cancer therapy and imaging in vivo..
11:9095S-9095S.
2005
-
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia..
11:8413-8417.
2005
-
Irrational exuberance in clinical proteomics..
11:7963-7964.
2005
-
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study..
11:8109-8113.
2005
-
The progress and promise of molecular imaging probes in oncologic drug development..
11:7967-7985.
2005
-
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors..
11:8145-8157.
2005
-
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon..
11:6116-6126.
2005
-
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model..
11:5622-5630.
2005
-
Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer..
11:5433-5439.
2005
-
Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy..
11:5566-5571.
2005
-
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer..
11:5233-5240.
2005
-
Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy..
11:5206-5214.
2005
-
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer..
11:5045s-5050s.
2005
-
Future of early detection of lung cancer: the role of mouse models..
11:4999s-5003s.
2005
-
Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer..
11:4968-4976.
2005
-
Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors..
11:4357-4364.
2005
-
Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk..
11:4620-4626.
2005
-
Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer..
11:4056-4066.
2005
-
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia..
11:4225-4233.
2005
-
In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors..
11:3930-3938.
2005
-
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers..
11:3686-3696.
2005
-
The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness..
11:3601-3603.
2005
-
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity..
11:3514-3522.
2005
-
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules..
11:3017-3024.
2005
-
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development..
11:2785-2808.
2005
-
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model..
11:2337-2344.
2005
-
Article on the enforced expression of wild-type p53 and the transcription of the O-6 -methylguanine-DNA methyltransferase gene (vol 7, pg 1398, 2001).
11:2449-2449.
2005
-
Erratum: Enforced expression of wild-type p53 curtails the transcription of the O6
-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents (Clinical Cancer Research (May 1, 2001) 7 (1398-1409)).
11:2449.
2005
-
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B..
11:2300-2304.
2005
-
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer..
11:2215-2221.
2005
-
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480..
11:1815-1820.
2005
-
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins..
11:1110-1118.
2005
-
Estrogen, estrogen plus progestin therapy, and risk of breast cancer..
11:909s-917s.
2005
-
Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications..
11:878s-883s.
2005
-
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells..
11:440-449.
2005
-
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668..
11:678-689.
2005
-
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference summary statement.
11.
2005
-
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement..
11:861s-864s.
2005
-
Tamoxifen versus aromatase inhibitors for breast cancer prevention..
11:925s-930s.
2005
-
The molecular pharmacology of estrogen receptor modulators: Implications for the treatment of breast cancer.
11.
2005
-
The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer..
11:871s-877s.
2005
-
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer..
11:284-289.
2005
-
Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia..
11:20-27.
2005
-
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.
11:440-449.
2005
-
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer..
11:113-122.
2005
-
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
11:678-689.
2005
-
Carbonic anhydrase IX in early-stage non-small cell lung cancer..
10:7925-7933.
2004
-
Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck..
10:7903-7910.
2004
-
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer..
10:7136-7143.
2004
-
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer..
10:6993-7000.
2004
-
Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications..
10:6586-6597.
2004
-
Bevacizumab for patients with metastatic renal cancer: an update..
10:6367S-6370S.
2004
-
Debulking nephrectomy in metastatic renal cancer..
10:6335S-6341S.
2004
-
Innovations and challenges in renal cancer: consensus statement from the first international conference..
10:6277S-6281S.
2004
-
Novel antiangiogenic therapies for renal cell cancer..
10:6377S-6381S.
2004
-
The von Hippel-Lindau tumor suppressor gene and kidney cancer..
10:6290S-6295S.
2004
-
Therapeutic options for variant renal cancer: a true orphan disease..
10:6393S-6396S.
2004
-
Tyrosine kinase inhibitors in renal cell carcinoma..
10:6371S-6376S.
2004
-
Mammalian target of rapamycin inhibition..
10:6382S-6387S.
2004
-
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid..
10:6397S-6403S.
2004
-
The role of hyperthermia in regional alkylating agent chemotherapy..
10:5919-5929.
2004
-
Patterns of chromosomal alterations in breast ductal carcinoma in situ..
10:5160-5167.
2004
-
Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant..
10:5076-5086.
2004
-
DNA array-based gene profiling in tumor immunology..
10:4597-4606.
2004
-
Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus..
10:4831-4838.
2004
-
Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer..
10:4287-4293.
2004
-
HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors..
10:4083-4088.
2004
-
Promoter hypermethylation profile of kidney cancer..
10:3972-3979.
2004
-
Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma..
10:3996-4002.
2004
-
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis..
10:3291-3300.
2004
-
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme..
10:3216-3224.
2004
-
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma..
10:2584-2586.
2004
-
Glutathione S-transferase polymorphisms and survival in primary malignant glioma..
10:2618-2625.
2004
-
Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy..
10:2609-2617.
2004
-
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response..
10:2253-2264.
2004
-
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer..
10:1963-1970.
2004
-
A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells..
10:1439-1445.
2004
-
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes..
10:828-839.
2004
-
Overcoming methodological weakness in dose-intense alkylating agent studies through pharmacology..
10:413-414.
2004
-
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors..
10:33-42.
2004
-
Global Expression Analysis of Well-Differentiated Pancreatic Endocrine Neoplasms Using Oligonucleotide Microarrays.
9:5988-5995.
2003
-
Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays..
9:5988-5995.
2003
-
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer..
9:5514-5520.
2003
-
Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761..
9:5630-5635.
2003
-
Targeting HER2 in brain metastases from breast cancer..
9:5435-5436.
2003
-
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer..
9:4396-4403.
2003
-
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
9:3534-3545.
2003
-
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors..
9:4247-4254.
2003
-
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
9:3534-3545.
2003
-
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer..
9:3534-3545.
2003
-
Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung..
9:3098-3104.
2003
-
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients..
9:2545-2550.
2003
-
Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans..
9:2510-2519.
2003
-
Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis..
9:2620-2626.
2003
-
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors..
9:2066-2071.
2003
-
Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response..
9:1728-1733.
2003
-
Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts..
9:1868-1876.
2003
-
Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase..
9:1155-1160.
2003
-
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer..
9:991-997.
2003
-
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma..
9:555-561.
2003
-
High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival..
9:762-766.
2003
-
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia..
9:663-668.
2003
-
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival..
9:613-618.
2003
-
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor..
9:586-593.
2003
-
Function of nuclear factor kappaB in pancreatic cancer metastasis..
9:346-354.
2003
-
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma..
8:3686-3695.
2002
-
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)..
8:3496-3502.
2002
-
Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells..
8:3628-3638.
2002
-
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420..
8:2812-2819.
2002
-
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts..
8:3000-3007.
2002
-
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation..
8:2260-2265.
2002
-
Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium..
8:1702-1709.
2002
-
Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation..
8:1172-1177.
2002
-
Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity..
8:1203-1209.
2002
-
Importance of serum hemoglobin in hormone refractory prostate cancer..
8:1049-1053.
2002
-
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer..
8:698-705.
2002
-
A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM..
7:3665S-3665S.
2001
-
Characterization of molecular mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea alone or in combination with O-6-benzylguanine in human medulloblastoma and rhabdomyosarcoma cell lines..
7:3739S-3739S.
2001
-
Dietary glycine reduces wound healing response and tumor growth by inhibition of angiogenesis: Introduction of a new method to screen anti- and pro-angiogenic compounds..
7:3704S-3704S.
2001
-
Effects of soluble Tie-2 receptor and bFGF on GFP-4T1 tumor growth and initiation of angiogenesis in BALB/C mouse dorsal skinfold window chamber..
7:3658S-3658S.
2001
-
Peptidyl-camptothecins are effective topoisomerase I inhibitors and potent antitumor agents..
7:3795S-3795S.
2001
-
Pharmacokinetics of CPT-11 in glioma patients: Pooled analysis of data from 4 NCI-sponsored trials (Duke university, NABTC, NABTT, NCCTG)..
7:3737S-3737S.
2001
-
Ritterazine B, a new cytotoxic marine product, induces apoptosis and G2/M arrest..
7:3716S-3716S.
2001
-
Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors..
7:3625-3628.
2001
-
The FLT3 internal tandem duplication in normal karyotype adult de novo AML lacking the wildtype FLT3 gene predicts poor prognosis: A Cancer and Leukemia Group B study..
7:3767S-3767S.
2001
-
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers..
7:2854-2861.
2001
-
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma..
7:2246-2253.
2001
-
The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats..
7:2590-2596.
2001
-
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299..
7:2031-2040.
2001
-
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480..
7:1932-1936.
2001
-
Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting..
7:1577-1581.
2001
-
Assays for monitoring cellular immune responses to active immunotherapy of cancer..
7:1127-1135.
2001
-
Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents..
7:1398-1409.
2001
-
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines..
7:1087-1093.
2001
-
Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer..
7:846-853.
2001
-
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer..
7:562-569.
2001
-
Glutathione conjugate of camptothecin is cytotoxic and enhances the stability of the topoisomerase I-DNA cleavage complex..
6:4511S-4511S.
2000
-
Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors..
6:4542S-4543S.
2000
-
Patients' perceptions of a high-profile phase 1 trial..
6:4575S-4575S.
2000
-
Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models..
6:4359-4364.
2000
-
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models..
6:4110-4118.
2000
-
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft..
6:4154-4157.
2000
-
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats..
6:4148-4153.
2000
-
Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas..
6:3748-3755.
2000
-
Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?.
6:2967-2968.
2000
-
Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers..
6:2999-3005.
2000
-
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2..
6:3334-3341.
2000
-
Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer..
6:2913-2920.
2000
-
Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display..
6:2835-2843.
2000
-
Temozolomide and treatment of malignant glioma..
6:2585-2597.
2000
-
The relationship between intracellular and extracellular pH in spontaneous canine tumors..
6:2501-2505.
2000
-
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms..
6:1936-1948.
2000
-
Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors..
6:1293-1301.
2000
-
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models..
6:998-1007.
2000
-
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238..
6:709-717.
2000
-
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473..
5:3942-3947.
1999
-
The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer..
5:4119-4125.
1999
-
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4..
5:4279-4286.
1999
-
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer..
5:3411-3418.
1999
-
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant..
5:3425-3431.
1999
-
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma..
5:3403-3410.
1999
-
Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic..
5:3711-3721.
1999
-
Molecular modeling based design of novel anticancer therapeutics that target the active sites of polymorphic GSTP1 proteins..
5:3841S-3841S.
1999
-
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4..
5:3755S-3756S.
1999
-
Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score..
5:2476-2484.
1999
-
Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1..
5:2646-2652.
1999
-
Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease..
5:1731-1737.
1999
-
125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts..
5:1539-1549.
1999
-
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen..
5:1331-1338.
1999
-
I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
5:1539-1549.
1999
-
Treatment of neoplastic meningitis with intrathecal temozolomide..
5:1183-1188.
1999
-
A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies..
5:831-837.
1999
-
Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers..
5:791-800.
1999
-
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea..
5:747-751.
1999
-
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel..
5:501-506.
1999
-
The prognostic significance of angiogenesis in epithelial ovarian carcinoma..
5:587-591.
1999
-
Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers..
5:335-341.
1999
-
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer..
5:209-213.
1999
-
Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma..
5:25-33.
1999
-
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells..
5:119-127.
1999
-
Gamma-ray mutagen sensitivity and survival in patients with glioma..
4:3031-3035.
1998
-
Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines..
4:3069-3076.
1998
-
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics..
4:3005-3010.
1998
-
Frequency of germline and somatic BRCA1 mutations in ovarian cancer..
4:2433-2437.
1998
-
Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent..
4:2495-2502.
1998
-
Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer..
4:2095-2102.
1998
-
The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody..
4:2071-2077.
1998
-
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)..
4:1887-1898.
1998
-
Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck..
4:1773-1778.
1998
-
Analysis of DNA mismatch repair proteins in human medulloblastoma..
4:1415-1419.
1998
-
Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo..
4:993-1004.
1998
-
Docetaxel enhances tumor radioresponse in vivo..
3:2431-2438.
1997
-
Loss of uteroglobin expression in prostate cancer: relationship to advancing grade..
3:2295-2300.
1997
-
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas.
3:2253-2261.
1997
-
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas..
3:2253-2261.
1997
-
Prognostic significance of glutathione S-transferase π expression and subcellular localization in human gliomas.
3:2253-2261.
1997
-
Untitled.
3:1455-1455.
1997
-
Docetaxel enhances tumor radioresponse in vivo.
3:2431-2438.
1997
-
Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model..
3:63-70.
1997
-
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome..
2:2015-2022.
1996
-
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor..
2:1489-1497.
1996
-
Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells..
2:1571-1575.
1996
-
Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden..
2:1405-1409.
1996
-
Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer..
2:1103-1105.
1996
-
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results..
2:963-972.
1996
-
Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer..
2:59-68.
1996
-
Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis..
1:1545-1555.
1995
-
Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome..
1:1589-1594.
1995
-
p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy..
1:1295-1300.
1995
-
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors..
1:859-864.
1995
-
Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients..
1:659-664.
1995
-
Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma..
18:1818.
2012
-
Correction: Article on genomic and molecular profiling to predict response to temozolomide (Clinical Cancer Research (2009) 15, (502-510)).
15:3240.
2009
-
Wound angiogenesis in healthy volunteers using OPSI technology: A potential surrogate marker for antiangiogenesis agents..
7:3700S-3700S.
2001
-
Association of pretreatment BMI with risk of head and neck cancer: A large-scale single-center study
2020
-
Generation and comparison of CRISPR/Cas9 and Cre-mediated genetically engineered mouse models of sarcoma
2018
-
Injury promotes sarcomagenesis.
2018
-
Modeling the tumor microenvironment in sarcoma: The impact on MPNST biology and chemotherapeutic response.
2018
-
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
2017
-
A phase I trial of AP23573, a novel mTOR inhibitor, in patients (Pts) with recurrent malignant glioma.
2005
-
Evaluation of bortezomib against childhood tumor models by the pediatric preclinical testing program (PPTP)
2005
-
Expression profiling of CD4+ and CD8+ T cells in malignant glioma.
2005
-
Gene expression models for recurrence risk prediction coupled with patterns of oncogenic pathway deregulation provide a novel therapeutic strategy for patients with non-small cell lung carcinoma.
2005
-
PI3K and TGF beta pathways interact functionally and therapeutically to regulate cellular motility and invasion in malignant glioma.
2005
-
The molecular pharmacology of estrogen receptor modulators: Implications for the treatment of breast cancer
2005
-
Androgen receptor downregulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
2003
-
Astatine-211 labeled Herceptin: An alpha-particle emitting radiotherapeutic.
2003
-
Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
2003
-
SB431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma xenograft malignant phenotype.
2003
-
ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.
2003
-
Evaluation of new expression-based markers for detection of breast cancer cells.
2001